2025-09-28 - Analysis Report
Okay, here's a comprehensive analysis of Merck & Co Inc (MRK) based on the data you've provided.

## Merck & Co Inc (MRK) Analysis

**Company Overview:** Merck & Co Inc is a global pharmaceutical company that develops and markets a broad range of healthcare products.

### 1. Performance vs. S&P 500 (VOO)

*   **Cumulative Returns:**
    *   MRK: -13.54%
    *   VOO: 66.41%
    *   Difference: -86.0%

*   **Disparity Analysis:** MRK has significantly underperformed the S&P 500 (VOO) over the analyzed period.

*   **Relative Disparity:** 0.8 (This suggests MRK's underperformance is near its historical worst relative to VOO within the provided data range).

*   **Alpha and Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha    | Beta   | Cap(B) |
|------------|---------|--------|----------|--------|--------|
| 2015-2017  | -2.0%   | 68.5%  | -11.0%   | -0.0   | 134.1  |
| 2016-2018  | 35.0%   | 64.1%  | 36.0%    | 0.0    | 182.1  |
| 2017-2019  | 37.0%   | 64.1%  | 33.0%    | 0.1    | 216.8  |
| 2018-2020  | 13.0%   | 79.5%  | -12.0%   | 0.2    | 195.0  |
| 2019-2021  | -7.0%   | 79.5%  | -36.0%   | 0.6    | 191.4  |
| 2020-2022  | 9.0%    | 79.5%  | -5.0%    | 0.6    | 277.1  |
| 2021-2023  | 25.0%   | 79.5%  | 8.0%     | 0.3    | 272.3  |
| 2022-2024  | -2.0%   | 79.5%  | -15.0%   | 0.2    | 248.5  |
| 2023-2025  | -50.0%  | 71.5%  | -86.0%   | -1.4   | 196.2  |

*   **Analysis:** The table highlights periods of both positive and negative alpha, suggesting MRK's performance has varied significantly relative to the market. The recent years (2018-2025) show significant underperformance (negative Alpha) and high risk (MDD). Especially in the 2023-2025 period, alpha and beta have dropped sharply.

### 2. Recent Stock Price Movements

*   **Current Price:** 78.56
*   **Previous Close:** 77.6
*   **Change:** 1.24
*   **5-day Moving Average:** 79.204
*   **20-day Moving Average:** 82.2352
*   **60-day Moving Average:** 82.3944

*   **Analysis:** The stock price is currently below its 5, 20, and 60-day moving averages, suggesting a short-term downtrend. The recent price increase (change of 1.24) may indicate a short-term rebound.

### 3. Technical Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 26.47 (Oversold)
*   **PPO:** -0.69 (Below zero line, indicating bearish momentum)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (191 shares - Very Safe - MRI:0.90)
*   **Recent (20-day) Relative Disparity Change:** 0.5 (+) (Short-term increase)
*   **Expected Return:** -1853.0% (Significant underperformance vs. S&P 500 if investing long-term now)

*   **Analysis:** While the MRI suggests high investment suitability, other indicators provide a mixed view. The RSI indicates the stock may be oversold and due for a bounce. The PPO indicates bearish momentum. The large, negative expected return is concerning and suggests that based on current trends, long-term investment may significantly underperform the market. The positive change in relative disparity suggests recent relative improvement compared to S&P 500. The Hybrid Signal indicates the algorithm recommends buying.

### 4. Recent News & Significant Events

*   **FDA Approval of Subcutaneous KEYTRUDA QLEX:** Positive news, likely to boost investor confidence.
*   **Merck (MRK) Outperforms Broader Market:** Contradicts the overall data, but suggests some recent positive momentum.
*   **Trump's Pharma Tariff Threat:** Creates uncertainty and potential risks for the pharmaceutical industry, including Merck.

### 4-2. Analyst Opinions

*   **Consensus:** Buy (~2.00)
*   **Target Price (avg/high/low):** 101.60 / 141.00 / 82.00
*   **Recent Rating Changes:** Not specified in detail, but should be monitored for insights into analyst sentiment.

*   **Analysis:** Analysts generally have a positive outlook on MRK, with a consensus rating of "Buy" and an average target price significantly above the current price.

### 5. Recent Earnings Analysis

| 날짜       | EPS    | 매출        |
|------------|--------|-------------|
| 2025-08-05 | 1.76   | 15.81 B$    |
| 2025-05-02 | 2.01   | 15.53 B$    |
| 2024-11-06 | 1.25   | 16.66 B$    |
| 2024-08-05 | 2.15   | 16.11 B$    |
| 2025-08-05 | 2.15   | 16.11 B$    |

*   **Analysis:** Recent EPS results have been mixed. The recent revenue have fluctuated within a relatively narrow range.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $15.81B   | 77.50%        |
| 2025-03-31 | $15.53B   | 77.98%        |
| 2024-12-31 | $15.62B   | 75.50%        |
| 2024-09-30 | $16.66B   | 75.51%        |
| 2024-06-30 | $16.11B   | 76.76%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE      |
|------------|-----------|----------|
| 2025-06-30 | $48.99B   | 9.04%    |
| 2025-03-31 | $48.34B   | 10.51%   |
| 2024-12-31 | $46.31B   | 8.08%    |
| 2024-09-30 | $44.50B   | 7.09%    |
| 2024-06-30 | $43.58B   | 12.52%   |

*   **Analysis:** Revenue has been relatively stable. Profit margins are consistently high. Equity has shown a steady increase. ROE has fluctuated, indicating variability in the company's ability to generate profit from shareholder equity.

### 7. Summary Analysis

Based on the provided data, MRK presents a mixed investment picture:

*   **Negative Factors:** Significant underperformance compared to the S&P 500, bearish technical indicators (PPO), and a concerningly negative expected return suggest potential risks.
*   **Positive Factors:** Recent FDA approval and analyst "Buy" ratings suggest potential for future growth. High MRI indicates high investment suitability, RSI indicates oversold conditions which may induce short term rebound.
*   **Mixed Factors:** Recent News of outperforming broader market, Recent relative disparity indicates recent relative improvement compared to S&P 500.
*   **Important Considerations:**  The potential impact of Trump's proposed drug tariffs adds uncertainty.

**Conclusion:**

MRK's current situation warrants caution. While analyst opinions are generally positive and there are recent positive developments (FDA approval), the underperformance relative to the S&P 500 and bearish technical indicators cannot be ignored. Investors should carefully weigh these factors and conduct further research before making any investment decisions. Close monitoring of the news, earnings reports, and regulatory environment is crucial.
